Veru (NASDAQ:VERU – Get Free Report) is expected to be releasing its earnings data before the market opens on Thursday, February 6th. Analysts expect Veru to post earnings of ($0.08) per share and ...

It's also important to note that Style Scores work as a complement to the Zacks Rank, our stock rating system that has an impressive track record of outperformance. Veru Inc. Currently has a Zacks ...

Veru's enobosarm showed significant body composition benefits in Phase 2b trials with semaglutide. Extension study results are due in April 2025.

Oppenheimer reiterated its Outperform rating and $5.00 price target for Veru Inc. (NASDAQ:VERU) shares, following the ...

The scale of the decline in Veru's shares despite the positive result may reflect the amplified expectations of investors for ...

InvestingPro data shows the stock has demonstrated strong resilience, often moving independently of broader market trends. The focus is on the potential of enobosarm, Veru's investigational drug ...